ArticleHereditary cancer in clinical practice2018
Article in Hereditary cancer in clinical practice, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Systematic review of the molecular basis of hereditary breast and ovarian cancer syndrome in Brazil: the current scenario.European journal of medical research · 2024Pooled it
- Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine.PharmacoEconomics · 2021Pooled it
- Copy number variants in BRCA1 and BRCA2 genes in Polish patients with breast and ovarian cancer.Journal of cancer research and clinical oncology · 2026Article
- Functional analysis of a splicing variant of the DOCK8 gene in a patient with breast cancer (Buryat ethnicity).Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Hereditary ovarian cancer.Discover oncology · 2026Review
- A prospective observational study of pancreatic cancer risk in men and women with pathogenic variants in BRCA1 or BRCA2.BJC reports · 2025Article
- Mutational spectrum and profile of breast and ovarian cancer patients in Saudi Arabia's western region: single center experience.Discover oncology · 2025Article
- Comprehensive germline and somatic profiling of high-risk Thai breast cancer via next-generation sequencing.Scientific reports · 2025Article
- Clinically SignificantCancers · 2024Article
- Germline sequence variation in cancer genes in Rwandan breast and prostate cancer cases.NPJ genomic medicine · 2024Article
- Article
- Tumor microenvironment and cancer metastasis: molecular mechanisms and therapeutic implications.Frontiers in pharmacology · 2024Review
- Comparing Prognosis forCancers · 2023Article
- Article
- Landscape of germlineFrontiers in oncology · 2023Article
- Genetic diversity in Kashubs: the regional increase in the frequency of several disease-causing variants.Journal of applied genetics · 2022Review
- BRCA1 Norway: comparison of classification for BRCA1 germline variants detected in families with suspected hereditary breast and ovarian cancer between different laboratories.Familial cancer · 2022Article
- Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic IntronicGenes · 2022Article
- Authorship Patterns in Cancer Genomics Publications Across Africa.JCO global oncology · 2021Article
- Identification ofFrontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFounder mutations in the two breast cancer genes,
methodsA total of 2430
resultsThere were 120 different
conclusionsThe spectrum of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.